Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05811247 · ClinicalTrials.gov registry record · Phase 3
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
A Phase 3 study of OSA, sponsored by Apnimed.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
- 20
- Study locations
NCT05811247 is a Phase 3 study of OSA that has completed, run by Apnimed. The registered enrollment target is 660 participants, above the 118-participant average among 14 other OSA trials with a reported enrollment target (459% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT05811247, a Phase 3 study of OSA, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AD109
Study Locations (20)
California
- Orange County Research Institute - Anaheim
- Marvel Clinical Research, LLC - Huntington Beach
- CenExel CNS - Los Alamitos
- Santa Monica Clinical Trials - Los Angeles
- Empire Clinical Research - Pomona
- Pacific Research Network - San Diego
- SDS Clinical Trials Inc. - Santa Ana
Florida
- Teradan Clinical trials LLC - Brandon
- St. Francis Medical Institute - Clearwater
- Nouvelle Clinical Research - Cutler Bay
- Arrow Clinical Trials - Daytona Beach
- Cenexel Research Centers of America - Hollywood - Hollywood
- Ivetmar Medical Group LLC - Miami
- PharmaDev Clinical Research Institute, LLC - Miami
Colorado
- Alpine Clinical Research Center - Boulder
- Mountain View Clinical Research, Inc. - Denver
Alabama
- Sleep Disorders Center of Alabama - Birmingham
Arizona
- Chandler Clinical Trials - Chandler
Arkansas
- Preferred Research Partners, Inc. - Little Rock
Connecticut
- Nuvance Health - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2023-08-28 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05811247
The ClinicalTrials.gov registry entry for NCT05811247 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 118-participant average among 14 other OSA trials with a reported enrollment target (459% higher). The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with OSA appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05811247 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT05811247 about?
NCT05811247 is a clinical study titled "Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)". This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
What is the current status of trial NCT05811247?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2023-08-28. Estimated completion is 2025-05-07.
What conditions does trial NCT05811247 study?
This clinical trial studies the following conditions: OSA.
What interventions are being tested in trial NCT05811247?
The interventions under investigation include: Placebo (DRUG), AD109 (DRUG).
Who is sponsoring clinical trial NCT05811247?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05811247 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OSA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA
RECRUITING · Phase 1
-
Diagnosing Obstructive Sleep Apnea Using Electromyography of the Muscles of the Mouth
RECRUITING
-
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
RECRUITING · Phase 1
-
Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.